Mirum Pharmaceuticals MIRM 深 沪
等待开盘 08-28 09:30:00 美东时间
99.75
+1.240
+1.26%
华盛通- 最 高100.095
- 今 开97.94
- 成交量 40.21万股
- 最 低 96.01
- 昨 收 98.51
- 总市值 64.77亿
- 52周最高 130.00
- 市盈率 静 --
- 换手率 0.62%
- 52周最低 63.232
- 委 比 81.35%
- 总股本 6493.22万
- 历史最高 130.00
- 量 比 0.81
- 振 幅 4.15%
- 历史最低 6.513
- 每 手 1
- 风险率 15.85%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Citizens Reiterates Market Outperform on Mirum Pharmaceuticals, Maintains $137 Price Target
Citizens analyst Jonathan Wolleben reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Outperform and maintains $137 price target.
08-27 22:01
ProQR a new buy at BoA on RNA-editing platform
Bank of America Securities has initiated coverage of ProQR Therapeutics (PRQR) at buy, saying that the company's Axiomer RNA-editing platform has been validated, supporting its pipeline. The bank has...
08-20 21:49
Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors
Cocrystal Pharma appoints Carol Brosgart, MD, to its Board of Directors. Dr. Brosgart, with decades of experience in antiviral therapy and epidemiology, will contribute to advancing the company's antiviral pipeline, including CDI-988 for norovirus. She previously worked at Gilead Sciences and holds leadership roles at multiple biotech companies. Cocrystal focuses on developing novel antiviral therapeutics targeting noroviruses, influenza, coronav...
08-17 15:17
美股大行评级 | 花旗、富国下调闪迪目标价，低至1400美元；百济神州、多邻国、DoorDash、Shopify等获多家机构上调评级
今日重点评级关注：康托·菲茨杰拉德：维持EyePoint"超配"评级，目标价从47美元升至55美元；伯恩斯坦：维持Figure Technology"跑赢大市"评级，目标价从67美元升至70美元
08-07 13:41
美股夜盘 | SiTime Corporation暴升32.41%，SoundHound AI暴升23.17%
SiTime Corporation暴升32.41%；SoundHound AI暴升23.17%；Caris Life Sciences劲升12.22%
08-06 15:01
美股夜盘 | SiTime Corporation暴升32.82%，SoundHound AI暴升24.57%
SiTime Corporation暴升32.82%；SoundHound AI暴升24.57%；Paycom Software劲升13.17%
08-06 13:01
财报速睇 | Mirum Pharmaceuticals 2026财年Q2营收1.76亿美元，同比增长37.9%；归母净利润亏损0.67亿美元，同比亏损扩大1047.0%
华盛资讯8月6日讯，Mirum Pharmaceuticals公布2026财年Q2业绩，公司Q2营收1.76亿美元，同比增长37.9%，归母净利润亏损0.67亿美元，同比亏损扩大1047.0%。
08-06 09:24
Mirum Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q2 adjusted EPS results.
Mirum Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q2 adjusted EPS results.
08-06 04:46
Mirum Pharmaceuticals Raises FY2026 Sales Guidance from $660.000M-$680.000M to $680.000M-$700.000M vs $675.249M Est
Mirum Pharmaceuticals (NASDAQ:MIRM) raises FY2026 sales outlook from $660.000 million-$680.000 million to $680.000 million-$700.000 million vs $675.249 million estimate.
08-06 04:04
